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Letters to the Editor
108Revising consensus in portal hypertension
Report of the Baveno V Consensus Workshop on methodology of
diagnosis and therapy in Portal HypertensionThis is a reply to the Letter to the Editor by Qi et al.
We read with great interest the letter by Dr. Qi et al. [1]. We do
agree with them that, at times, it is difﬁcult to make a precise
diagnosis of acute and chronic portal vein thrombosis on the
basis of contrast enhanced CT alone, especially if it is in the tran-
sition period and the disease is evolving. In making a proper diag-
nosis, one needs to take into account the natural history,
including the rapidity of development of the thrombus, the
appearance of symptoms, the extent of the thrombosis, and the
development of complications. Previous and present attempts
by the same group of workers [1,2] and by others [3] have only
looked at the degree and duration of the development of PVT.
The ﬁgures enclosed with the present communication [1] clearly
show opening-up of various porto–porto collateral channels and
development of a cavernoma. Of course, it is not easy to hypoth-
esize the age of the cavernoma, in the absence of full clinical
details. A Doppler ﬂow image would have been quite helpful to
determine the nature of the thrombosis and the degree of
involvement of splanchnic circulation. A second look at the con-
sensus statements of the Baveno V [4] may help clarify the situ-
ation in the patient under consideration. A recent thrombosis is
deﬁned as non-enhancing material within the portal vein (PV)
with increased hepatic enhancement in the arterial phase. It is
important to note that the recommendations are that a CT/MR
angiography is more helpful to determine the nature of the
thrombosis. In the given case, the collaterals are already
enhanced in the CT images after the contrast injection. There is,
however, a non-enhanced material also seen inside the PV, sug-
gestive of a possible recent thrombosis.
It is well known that in patients with EHPVO, thrombosis
could be an ongoing process, and both clinical situations could
co-exist. However, once the cavernoma forms, there remains no
doubt about the process being chronic. Because of these reasons,
the proposed nomenclature by Dr. Qi et al. of partial and com-
plete in both acute and chronic stages seems a bit empirical. All
these issues were discussed in the Baveno meeting. Further, the
Baveno statement clearly mentions the role of both Color Doppler
ultrasound and the contrast enhanced US to conﬁrm the recent
thrombosis and differentiate it from the chronic thrombosis; a
yard-stick, which was not followed by the authors [1].2 Journal of Hepatology 201In the Baveno V conference, a detailed discussion on different
clinical scenarios of EHPVO was presented by us and was then
deliberated at length by global experts. A comprehensive consen-
sus classiﬁcation was ﬁnally approved (manuscript under prepa-
ration). The consensus statement reads ‘‘Baveno classiﬁcation of
EHPVO: This classiﬁcation utilizes ﬁve main characteristics of
portal vein obstruction, namely: the site of obstruction (trunk
or branches), the clinical presentation (recent or chronic), nature
of underlying liver disease, the degree of occlusion and the extent
of involvement’’. Such a classiﬁcation is needed and once pub-
lished would hopefully be found useful for new studies, as it will
bring uniformity in reporting the results and comparing the
outcome.
We are delighted that Dr. Han and colleagues have looked into
the various complications of chronic EHPVO. In fact, several large
series have reported the long-term outcome of portal vein occlu-
sion. Development of portal biliopathy, progressive hepatic dys-
function as a result of chronic deprivation of blood ﬂow and
growth factors, and growth retardation (if the portal vein occlu-
sion has occurred in pre-pubertal age) are well known complica-
tions of chronic EHPVO [5]. These complications highlight the
need for early detection and intervention in such patients. It is
well accepted that the outcome of long standing portal biliopa-
thy, an entity identiﬁed nearly 20 years ago, remains dismal.
Endoscopic interventions and even surgical shunts do not fully
reverse the process [6,7]. It is associated with high morbidity
and mortality. Similarly, growth retardation is commonly seen
in nearly 30–50% of the subjects [8]. At the Baveno V meeting,
management of these complications was discussed. It was pro-
posed that Rex bypass (mesenterico-left portal bypass) in chil-
dren with EHPVO [9] has been shown to reverse complications
associated with EHPVO including retardation of growth
and development, minimal encephalopathy, coagulopathy, and
hypersplenism. It prevents portal hypertensive bleeding
and may prevent development of biliopathy. Of course, proper
patient selection and expertise would be required for optimal
outcome. Placement of TIPS stents and liver transplantation could
also be occasionally helpful. EHPVO remains a challenge for
hepatologists and we do hope that with a better understanding
of the pathophysiology and mechanisms of PV thrombosis, we1 vol. 54 j 1079–1083
may be able to prevent development of such thrombosis and/or
detect them early enough for proper repermeation.
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